Want to see AUNA full AI Analyst Report?
Top Page
Auna S.A. Class A
(NYSE:AUNA)
Select Model
Select Model
Rating:57Neutral
Price Target:
$5.50
▲(10.22% Upside)
Action:Reiterated
Date:05/22/26
The score is driven by mid-range financial quality: strong free cash flow and improved operating profitability are offset by high leverage and thin net margins. Technicals weigh on the score due to a clear downtrend despite oversold signals. Valuation is a supportive positive with a low P/E, while the earnings call is moderately constructive on reaffirmed guidance and cash generation but tempered by near-term margin and FX/leverage sensitivity.
Positive Factors
Strong cash generation
Consistent, sizable operating and free cash flow provides durable capacity to service debt, fund capex and support strategic projects. Over 2–6 months this underpins deleveraging plans and funds expansion (Torre Trecca, facility investments) without relying on volatile equity markets.
Negative Factors
High leverage and limited flexibility
Elevated leverage constrains financial flexibility and increases vulnerability to revenue slowdowns or interest shocks. Even with improved cash flow, high absolute debt levels limit ability to pursue opportunistic investments and slow the pace of deleveraging, posing multi-month balance‑sheet risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Consistent, sizable operating and free cash flow provides durable capacity to service debt, fund capex and support strategic projects. Over 2–6 months this underpins deleveraging plans and funds expansion (Torre Trecca, facility investments) without relying on volatile equity markets.
Read all positive factors
Auna S.A. Class A (AUNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$381.17M
Dividend YieldN/A
Average Volume (3M)446.37K
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue Growth11.49%
EPS Growth-57.82%
CountryUS
Employees15,254
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.27
Shares Outstanding30,095,388
10 Day Avg. Volume235,431
30 Day Avg. Volume446,366
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.31
Price to Sales (P/S)0.11
P/FCF Ratio3.08
Enterprise Value/Market Cap12.28
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit2.73
Enterprise Value/Ebitda5.92
Forecast
1Y Price Target
$5.00Price Target Upside0.20% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)3.01
Revenue Forecast (FY)$4.77B
Auna S.A. Class A Business Overview & Revenue Model
Company Description
Auna S.A. operates as a healthcare services provider, overseeing a network of hospitals and clinics across Mexico, Peru, and Colombia. The company also offers prepaid medical programs in Peru, alongside dental and vision insurance plans for client...
How the Company Makes Money
null...
Auna S.A. Class A Earnings Call Summary
Earnings Call Date:May 19, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 26, 2026
Earnings Call Sentiment Neutral
The call conveyed clear topline momentum and meaningful improvements in cash generation, liquidity and payer mix across Mexico, Peru and Colombia, supported by rising high-complexity volumes and strategic wins (OncoSalud B2B growth, new payer contracts, Torre Trecca progress). However, near-term profitability was pressured by Peru revenue reconciliations and delayed pharmacy rebates, noncash FX losses, and higher compensation costs which caused a consolidated adjusted EBITDA decline and margin compression. Management reaffirmed full-year revenue and EBITDA guidance and expects stronger second-half performance, positioning the company to convert current operational momentum into margin recovery and deleveraging over 2026.Positive Updates
Consolidated Revenue Growth
Consolidated revenue reached PEN 1.2 billion, growing 10% year-over-year in FX-neutral terms, with revenue increases across all segments.
Negative Updates
Consolidated Adjusted EBITDA Decline
Consolidated adjusted EBITDA decreased 5% FX-neutral and consolidated adjusted EBITDA margin contracted by 2.9 percentage points in Q1, driven by two extraordinary items (Peru revenue adjustments) and payroll increases.
Read all updates
Q1-2026 Updates
Positive
Negative
Consolidated Revenue Growth
Consolidated revenue reached PEN 1.2 billion, growing 10% year-over-year in FX-neutral terms, with revenue increases across all segments.
Read all positive updates
Company Guidance
Auna reaffirmed its 2026 revenue and adjusted‑EBITDA guidance and said it expects the bulk of growth in the second half of the year; in Q1 consolidated revenue was PEN 1.2 billion (+10% FX‑neutral) while consolidated adjusted EBITDA declined 5% FXN with margin down 2.9pp (impacted by Peru revenue adjustments and payroll), and management reiterated a medium‑term leverage target of 3.0x (Q1 leverage 3.7x) and that cash‑after‑interest generation should grow in 2026—cash was PEN 409m (+22%), free cash flow PEN 152m (2.6x YoY). Segment detail backing the guidance: Mexico revenue +8% with adjusted EBITDA +19% QoQ and +23% YoY (management cites a path back toward ~30% structural margins and >20% consolidated EBITDA margin), Peru revenue +9% (healthcare services +7%, OncoSalud +12%; EBITDA -3% but would be +7% excluding revenue adjustments), Colombia revenue +13% with risk‑sharing at 21% of segment revenue (up 6pp), new payers now 12% of revenue, and Colombia adjusted EBITDA +7% (margin down 1.7pp).Auna S.A. Class A Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
45
Neutral
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.52B | 4.39B | 4.39B | 3.88B | 2.45B | 1.92B |
| Gross Profit | 1.71B | 1.66B | 1.73B | 1.44B | 879.70M | 686.93M |
| EBITDA | 790.21M | 856.65M | 887.03M | 647.30M | 299.14M | 170.15M |
| Net Income | 68.14M | 97.61M | 110.27M | -253.92M | -85.61M | -26.47M |
Balance Sheet | ||||||
| Total Assets | 7.69B | 7.30B | 7.08B | 7.69B | 6.59B | 2.82B |
| Cash, Cash Equivalents and Short-Term Investments | 428.92M | 365.65M | 335.97M | 334.26M | 208.69M | 138.77M |
| Total Debt | 3.82B | 3.66B | 3.77B | 3.92B | 3.51B | 1.49B |
| Total Liabilities | 5.77B | 5.53B | 5.46B | 5.91B | 5.04B | 2.28B |
| Stockholders Equity | 1.74B | 1.60B | 1.48B | 1.47B | 1.06B | 495.82M |
Cash Flow | ||||||
| Free Cash Flow | 492.83M | 161.76M | 577.64M | 417.25M | 10.67M | -106.03M |
| Operating Cash Flow | 601.05M | 242.83M | 668.50M | 582.41M | 162.64M | 183.34M |
| Investing Cash Flow | -44.92M | -78.83M | -236.82M | -173.15M | -3.21B | -291.99M |
| Financing Cash Flow | -362.44M | -74.31M | -418.12M | -370.00M | 3.13B | -102.13M |
Auna S.A. Class A Technical Analysis
Neutral
4.99
Price Trends
4.88
Positive
5.13
Negative
5.20
Negative
Market Momentum
0.06
Positive
52.40
Neutral
21.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUNA, the sentiment is Neutral. The current price of 4.99 is below the 20-day moving average (MA) of 5.13, above the 50-day MA of 4.88, and below the 200-day MA of 5.20, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 52.40 is Neutral, neither overbought nor oversold. The STOCH value of 21.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AUNA.
Auna S.A. Class A Risk Analysis
Auna S.A. Class A disclosed 57 risk factors in its most recent earnings report. Auna S.A. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Auna S.A. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $874.42M | 1,108.51 | 1.03% | ― | 22.64% | -58.05% | |
59 Neutral | $293.47M | -25.30 | -12.42% | ― | -11.78% | 40.18% | |
59 Neutral | $427.74M | -4.34 | -27.10% | ― | -20.37% | -479.68% | |
57 Neutral | $381.17M | -64.28 | 4.10% | ― | 11.49% | -57.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.92B | -7.01 | -35.37% | ― | 25.25% | -96.16% | |
45 Neutral | $476.30M | -4.93 | 5.89% | ― | -2.87% | ― |
* Healthcare Sector Average
AUNA
Auna S.A. Class A
5.12
-1.23
-19.37%
SNDA
Sonida Senior Living
40.84
16.01
64.48%
CYH
Community Health
3.30
-0.45
-12.00%
CCRN
Cross Country Healthcare
13.24
-0.12
-0.90%
TALK
Talkspace
5.21
2.66
104.31%
AIRS
Airsculpt Technologies
4.45
-1.16
-20.68%
Auna S.A. Class A Corporate Events
Auna Shareholders Approve 2025 Accounts as Board Streamlines to Seven Members
Jul 7, 2026
On June 30, 2026, Auna S.A. held its annual general meeting of shareholders in Luxembourg, during which investors approved all proposals related to 2025 governance and financial reporting. These included confirmation of share awards to independent...
Auna S.A. Calls June 30, 2026 AGM to Approve 2025 Results and Governance Matters
May 27, 2026
Auna S.A. has convened its annual general meeting of shareholders for June 30, 2026 in Luxembourg, setting May 15, 2026 as the record date for holders of its Class A and Class B shares who wish to attend or vote. Shareholders may participate in pe...
Auna S.A. Posts Double-Digit 1Q26 Revenue Growth and Strong Cash Flow While Reaffirming 2026 Guidance
May 19, 2026
Auna S.A. reported first-quarter 2026 results on May 19, 2026, showing consolidated revenue up 10% in constant currency and 13% year over year to S/1,178 million, driven by local-currency growth of 8% in Mexico, 9% in Peru and 14% in Colombia. Adj...
Auna Files 2025 Form 20‑F, Boosting Transparency for Latin American Healthcare Platform
Apr 22, 2026
Auna S.A. is a Latin American healthcare company operating in Mexico, Peru and Colombia, focused on prevention and complex diseases that drive the highest healthcare spending. Founded in 1989, it has built a large integrated platform of hospitals,...
Auna S.A. Publishes Preliminary Q1 2026 Operating Metrics for Latin American Healthcare Platform
Apr 17, 2026
On April 17, 2026, Auna S.A. released preliminary key performance indicators for the quarter ended March 31, 2026, detailing volumes across its Mexican, Peruvian, and Colombian operations. The disclosure, which the company plans to repeat each qua...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.